Refocusing the Use of Psychiatric Drugs for Treatment of Gastrointestinal Cancers
| Autor: | Erik Lizárraga-Verdugo, Mercedes Bermúdez, Mariana Avendaño-Félix, César López-Camarillo, Maribel Aguilar-Medina, Rosalío Ramos-Payán |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Cancer Research psychiatric drugs Mini Review lcsh:RC254-282 gastric Metastasis 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine esophageal medicine PTEN cancer Protein kinase B PI3K/AKT/mTOR pathway Cisplatin colorectal biology business.industry Cancer food and beverages medicine.disease lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens 030104 developmental biology Paclitaxel chemistry Oncology Apoptosis 030220 oncology & carcinogenesis pancreatic Cancer research biology.protein business hepatic medicine.drug |
| Zdroj: | Frontiers in Oncology Frontiers in Oncology, Vol 10 (2020) |
| ISSN: | 2234-943X |
| DOI: | 10.3389/fonc.2020.01452 |
| Popis: | Gastrointestinal cancers (GICs) are the most common human tumors worldwide. Treatments have limited effects, and increasing global cancer burden makes it necessary to investigate alternative strategies such as drug repurposing. Interestingly, it has been found that psychiatric drugs (PDs) are promising as a new generation of cancer chemotherapies due to their anti-neoplastic properties. This review compiles the state of the art about how PDs have been redirected for cancer therapeutics in GICs. PDs, especially anti-psychotics, anti-depressants and anti-epileptic drugs, have shown effects on cell viability, cell growth, inhibition of proliferation (cell cycle arrest), apoptosis promotion by caspases activation or cytochrome C release, production of reactive oxygen species (ROS) and nuclear fragmentation over esophageal, gastric, colorectal, liver and pancreatic cancers. Additionally, PDs can inhibit neovascularization, invasion and metastasis in a dose-dependent manner. Moreover, they can induce chemosensibilization to 5-fluorouracil and cisplatin and can act synergistically with anti-neoplastic drugs such as gemcitabine, paclitaxel and oxaliplatin. All anti-cancer activities are given by activation or inhibition of pathways such as HDAC1/PTEN/Akt, EGFR/ErbB2/ErbB3, and PI3K/Akt; PI3K-AK-mTOR, HDAC1/PTEN/Akt; Wnt/β-catenin. Further investigations and clinical trials are needed to elucidate all molecular mechanisms involved on anti-cancer activities as well as adverse effects on patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|